Close menu

July 31st, 2023 | 09:50 CEST

BASF, Cantourage Group, Palantir - Now the analysts speak out

  • Cannabis
  • Software
  • chemicals
Photo credits:

Currently, it is high noon for the release of first-half 2023 earnings. Despite all the uncertainties regarding geopolitical and fiscal policy, the majority of companies surprised positively. As a result, the Dow Jones, DAX, Nasdaq and others were able to climb to new highs for the year. Analysts also see further upside potential for many companies, which could accelerate the rally in the coming weeks.

time to read: 4 minutes | Author: Stefan Feulner

Table of contents:

    Palantir - AI gives wings

    For a long time, data analytics software provider Palantir was not considered a friend of the analyst community due to its high valuation. But the explosive development of artificial intelligence, in which the US-Americans are likely to play a key role, is fundamentally changing the views of financial experts. The best example is the initial study of the US analyst firm Wedbush, which started the coverage with a price target of USD 25 and the verdict "outperform".

    Thus, according to their study, the analysts assume that Palantir, with its data pool built over decades, is in a position to take advantage of the growing opportunities offered by the major language models to expand its platform and enhance it. Palantir could thus leverage its expertise to drive the development of AI solutions based on high-quality data, thereby laying the groundwork for transitioning to a pure-play AI company. "Palantir has built an impregnable AI fortress and is positioned to play a critical role in the upcoming revolution of the next decade," the analysts wrote in their assessment last week.

    The financial experts also believe the stock could continue to be re-rated and should trade significantly above its software peer group over time. On the one hand, Palantir will continue to expand and, on the other, benefit from revolutionary AI.

    After a price performance of almost 150% to now USD 17.81 since the beginning of May, the next resistance at USD 19.45 should become decisive. Should the Nasdaq title cross this hurdle, a further move to the area around USD 27 would be possible. If the mark is not broken in the first attempt, there is a threat of a setback to the level of around USD 15.

    Cantourage Group - Different from the peer group

    When comparing the numbers of the German cannabis pioneer with companies like Canopy Growth or Tilray, which are still struggling with substantial losses in their balance sheets after years, Cantourage Group's performance can be considered nothing short of spectacular. With a growth surge of 90% in the first half of the year and a positive EBITDA, the North American peer group is as far away as the moon from achieving such results. The Berlin-based company, which went public in the fourth quarter, has a market capitalization of around EUR 137 million. In comparison, Canopy Growth has a market capitalization of EUR 253.58 million, and Tilray is even higher at EUR 1.03 billion.

    Cantourage Group, one of the leading European companies for the production and distribution of cannabis-based medicinal products, achieved revenues of approximately EUR 11.1 million in the first half of the year, an increase of around 90%. In addition, the Company achieved positive EBITDA for the second quarter in a row. At the half-year point, this amounted to EUR 0.2 million. The Company's management expects further strong, profitable growth in the high double-digit percentage range for the full year. According to a recent study by NuWays AG, analysts anticipate revenues of EUR 30.7 million for the current year. These revenues are expected to almost double the following year to around EUR 56.1 million. In addition, earnings per share are expected to continue to develop positively from EUR 0.01 per share to EUR 0.15 in 2024.

    An additional boost could come from the government's planned legal elimination of the classification of medical cannabis as a narcotic, which should make access to medical cannabis much easier. Currently, every customer still pays entirely out of their own pocket when purchasing medical preparations, with the exception of palliative patients or people with chronic conditions. Should health insurance companies step in in the future, the market is likely to explode.

    With its "Fast Track Access" platform, the Cantourage Group is pursuing a profitable business model compared to its competitors. By bringing in additional partners worldwide, there is also enormous growth potential. Due to the low free float, long-term investors should limit their purchases.

    BASF - Bottom reached

    The analysts' conference that followed the figures brightened the mood among BASF shareholders considerably. The reason was the fact that the management of the chemical company assumed no further weakening of demand and that the bottom had been reached. In addition, they were sticking to the IPO or the sale of the subsidiary Wintershall Dea. Moreover, the weak figures for the first half of the year were no longer a surprise in the sense that the Ludwigshafen-based company had already published its key data in mid-July and, like many companies in the chemicals sector, had lowered its forecasts for the year as a whole.

    For the current year, management has since calculated a decline in sales to EUR 73 to 76 billion, compared with EUR 87.3 billion in the previous year. Previously, the forecast was significantly higher at EUR 84 to 87 billion. In terms of operating profit, BASF now expects only EUR 4.0 billion to EUR 4.4 billion instead of EUR 4.8 billion to EUR 5.4 billion. In the previous year, the DAX-listed group had still achieved an operating result of just under EUR 6.9 billion.

    Following the publication of the figures, several analyst firms spoke out. The British investment bank Barclays left its rating for BASF at EUR 61 with an "equal-weight " vote. JP Morgan, on the other hand, has set its rating at "overweight". The US target price remains at EUR 58.

    Despite weak figures, BASF was able to reassure analysts with a positive outlook. According to financial experts, Palantir is one of the primary beneficiaries of the AI revolution. Revolutionary compared to the peer group are also the half-year figures of the cannabis company Cantourage Group.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Juliane Zielonka on February 22nd, 2024 | 07:00 CET

    Royal Helium, Fresenius, BASF: Chemical and Healthcare industry - Where is the next investment opportunity?

    • Helium
    • Healthcare
    • chemicals

    Europe is in the midst of an industrial upheaval due to the Green Deal, which presents both challenges and opportunities for investors. While companies like BASF are arguing for deregulation and increased subsidies to support the green transition, healthcare company Fresenius is undergoing a period of radical change and realignment. The medical technology market is booming. The global MedTech market size amounted to USD 574,002.45 million in 2022 and is expected to increase to USD 814,159.2 million by 2028, with an annual growth rate of 6.0%. Critical raw materials such as helium are in particularly high demand. Royal Helium is one of the producers of this valuable gas and impresses with a well thought-out and sustainable business model. Where does the next investment opportunity lie?


    Commented by Fabian Lorenz on February 21st, 2024 | 07:00 CET

    Top news: BYD, Bayer and Globex Mining

    • Mining
    • Gold
    • Commodities
    • Electromobility
    • chemicals

    Bayer shocked investors yesterday with the announcement of its dividend cut, which shouldn't have been much of a surprise. The Company is burdened with high debt, endless legal fines, and an empty pharmaceutical pipeline. In an initial reaction, analysts have lowered the share price target. BYD, on the other hand, is doing well operationally. Only the share price is not picking up. Will a share buyback turn the share price around? For those who want to profit from the commodity boom with reduced risk, then Globex Mining's stock is attractive. The news flow is strong, and those who act quickly can still register and follow the live presentation of the mining incubator at the 10th International Investment Forum, IIF, today.


    Commented by Armin Schulz on February 13th, 2024 | 07:00 CET

    TUI, Globex Mining, Palantir - Movement is possible here

    • Mining
    • Commodities
    • travel
    • Software

    Investors should have TUI, Globex Mining and Palantir on their watchlist, as they could be on the verge of movement. While TUI, as a leading tourism company, is showing signs of recovery after the pandemic, Globex Mining promises important impetus for the future of the industry and green technologies with its broad commodities portfolio. Palantir, on the other hand, known for its advanced data analytics platforms, is on the brink of significant growth opportunities in an increasingly data-rich era. In this context, movements are possible, and as an investor, one would want to be invested early. We highlight the potential of the three companies.